Autologous CD34+ cells: Phase I/II data

The open-label, Italian Phase I/II TIGET-MLD trial in 3 evaluable pre-symptomatic patients with evidence of

Read the full 159 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE